A shortened antiviral protocol adding the dyslipidemic agent ezetimibe can prevent infection in solid-organ recipients who receive hepatitis C virus–positive organs, according to new research presented at The Liver Meeting 2023.
The regimen, dubbed the “Toronto Protocol,” uses the current standard-of-care treatment glecaprevir-pibrentasvir (Mavyret, AbbVie) but cuts the course from eight weeks to eight days. It also adds ezetimibe, a cholesterol-lowering drug that has the